Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in Oncology

Journal Scan / Research · July 27, 2015

Results of Tivantinib (ARQ 197) Plus Erlotinib vs Erlotinib Alone Study in Advanced Non-Squamous NSCLC

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Journal of Clinical Oncology
Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib vs Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
J. Clin. Oncol 2015 Jul 13;[EPub Ahead of Print], G Scagliotti, J von Pawel, S Novello, R Ramlau, A Favaretto, F Barlesi, W Akerley, S Orlov, A Santoro, D Spigel, V Hirsh, FA Shepherd, LV Sequist, A Sandler, JS Ross, Q Wang, R von Roemeling, D Shuster, B Schwartz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated